<div id="readability-page-1"><p>Shares of OmniAb, Inc. (NASDAQ:OABI - Get Free Report) traded up 3.3% during mid-day trading on Wednesday . The company traded as high as $1.9250 and last traded at $1.90. 264,447 shares traded hands during mid-day trading, a decline of 52% from the average session volume of 547,383 shares. The stock had previously closed at $1.84.</p><h2>Wall Street Analysts Forecast Growth</h2><p>Separately, Weiss Ratings  restated a &#34;sell (e+)&#34; rating on shares of OmniAb in a research report on Monday, December 22nd. Three research analysts have rated the stock with a Buy rating and one  has issued  a Sell rating to the company's stock. According to data from MarketBeat.com, OmniAb presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $6.67.</p><p><b>Read Our Latest Stock Analysis on OmniAb</b></p><h2>OmniAb Stock Performance</h2><p>The firm has a 50 day simple moving average of $1.80 and a two-hundred day simple moving average of $1.78. The stock has a market cap of $273.52 million, a P/E ratio of -3.28 and a beta of 0.13. </p><p>OmniAb (NASDAQ:OABI - Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. OmniAb had a negative return on equity of 23.14% and a negative net margin of 301.83%.The company had revenue of $2.24 million during the quarter, compared to analysts' expectations of $5.64 million.  As a group, equities research analysts predict that  OmniAb, Inc. will post -0.61 EPS for the current year. </p><h2>Insider Buying and Selling at OmniAb</h2><p>In other OmniAb news, CFO Kurt A. Gustafson sold 23,922 shares of the firm's stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $1.96, for a total transaction of $46,887.12. Following the transaction, the chief financial officer owned 252,688 shares of the company's stock, valued at approximately $495,268.48. This trade represents a 8.65% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, CEO Matthew W. Foehr sold 13,666 shares of the business's stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $1.96, for a total transaction of $26,785.36. Following the sale, the chief executive officer owned 4,360,083 shares in the company, valued at $8,545,762.68. This trade represents a 0.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 45,632 shares of company stock valued at $89,439. Company insiders own  8.60% of the company's stock. </p><h2>Institutional Investors Weigh In On OmniAb</h2><p>A number of institutional investors have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio bought a new position in  OmniAb during the second quarter valued at about $168,000.  Connors Investor Services Inc. raised its position in  OmniAb by 25.0% in the second quarter. Connors Investor Services Inc. now owns 62,000 shares of the company's stock worth $108,000 after acquiring an additional 12,389 shares in the last quarter.  Towerview LLC lifted its holdings in  OmniAb by 43.3% in the 2nd quarter. Towerview LLC now owns 831,100 shares of the company's stock valued at $1,446,000 after acquiring an additional 251,100 shares during the last quarter.  Private Management Group Inc. boosted its position in shares of  OmniAb by 1.1% during the 2nd quarter. Private Management Group Inc. now owns 2,558,045 shares of the company's stock valued at $4,451,000 after purchasing an additional 28,286 shares in the last quarter.  Finally, Isthmus Partners LLC boosted its position in shares of  OmniAb by 21.2% during the 2nd quarter. Isthmus Partners LLC now owns 568,043 shares of the company's stock valued at $988,000 after purchasing an additional 99,336 shares in the last quarter. 72.08% of the stock is currently owned by institutional investors and hedge funds. </p><h2>OmniAb Company Profile</h2> (Get Free Report)<p>OmniAb, Inc <span>NASDAQ: OABI<span></span></span> operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas. </p><p>Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.</p><h2>See Also</h2><ul><li>Five stocks we like better than OmniAb</li><li>You Still Think Silver’s a Joke? Watch What Happens Next.</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li><li>A month before the crash</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>YDES Could Be 2026's Biotech Breakthrough</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in OmniAb Right Now?</h2><p>Before you consider OmniAb, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OmniAb wasn't on the list.</p><p>While OmniAb currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

OABI

<p>OmniAb (NASDAQ:OABI) shares rose 3.3% to $1.90, with a trading volume decline of 52% from the average. Analysts maintain a consensus rating of "Moderate Buy" and a target price of $6.67. The company reported a quarterly EPS of ($0.14), exceeding estimates, but revenue fell short at $2.24 million. Insider selling occurred, with CFO and CEO reducing their stakes. Institutional investors hold 72.08% of shares. OmniAb specializes in therapeutic antibody development and went public in May 2021.</p>

OmniAb (NASDAQ:OABI) Stock Price Up 3.3% - What's Next?